Anti-Obesity Drugs Market Recent Developments 2025: Key Updates from the U.S., Europe, Japan, and Asia-Pacific | Major Companies are Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb

Global Anti-Obesity Drugs Market reached US$ 2.5 billion in 2022 and is expected to reach US$ 43.7 billion by 2030 growing with a CAGR of 45.5% during the forecast period 2024-2031.

The anti-obesity drugs market includes pharmaceuticals designed to promote weight loss by suppressing appetite, reducing fat absorption, or enhancing energy expenditure. Rising global obesity rates, linked to sedentary lifestyles and unhealthy diets, are driving market demand. Approved drugs include orlistat, liraglutide, and emerging GLP-1 receptor agonists. The market is witnessing a shift toward safer, more effective drugs with fewer side effects. Increased awareness of obesity-related diseases like diabetes and cardiovascular disorders supports adoption. Expanding research pipelines and regulatory approvals are reshaping the competitive landscape.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Anti-Obesity Drugs Market Landscape:- https://datamintelligence.com/download-sample/anti-obesity-drugs-market?rk

☛ Anti-Obesity Drugs Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, Novo Nordisk expanded its GLP-1 receptor agonist portfolio for obesity management in the U.S., offering improved weight-loss efficacy and patient adherence.

✅ In July 2025, Eli Lilly launched next-generation anti-obesity therapies, targeting appetite regulation and metabolic health in adults with obesity.

✅ In June 2025, Pfizer partnered with U.S. healthcare providers to deploy innovative pharmacological treatments, supporting personalized obesity care plans.

Europe: Recent Industry Developments

✅ In July 2025, Novo Nordisk Europe introduced advanced anti-obesity drugs in EU markets, integrating patient support programs to improve long-term adherence.

✅ In June 2025, Sanofi launched novel pharmacotherapies for weight management, focusing on patients with obesity-related comorbidities.

✅ In May 2025, Eli Lilly Europe partnered with hospitals and clinics to implement next-generation obesity treatments, emphasizing metabolic improvements and cardiovascular health.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Pharmaceutical expanded its anti-obesity drug portfolio in Japan, addressing lifestyle-related obesity and metabolic syndrome.

✅ In June 2025, Novo Nordisk Japan launched GLP-1 based therapies for weight management, supporting sustainable lifestyle interventions.

✅ In May 2025, Astellas Pharma partnered with healthcare centers to provide innovative pharmacological solutions, enhancing patient outcomes in obesity care.

☛ Anti-Obesity Drugs Market Trends:

Anti-obesity drugs are used for weight management in patients with obesity or overweight-related comorbidities, including GLP-1 receptor agonists, appetite suppressants, and metabolic modulators. Market growth is fueled by rising global obesity prevalence, increasing health awareness, and demand for non-surgical weight loss options.

Innovations in long-acting therapies, combination drugs, and personalized obesity treatments are improving efficacy and patient compliance. North America and Europe lead due to high obesity rates and reimbursement coverage, while Asia-Pacific is rapidly growing due to lifestyle changes, urbanization, and expanding healthcare access. Cost, side effects, and treatment adherence are ongoing challenges.

☛ Anti-Obesity Drugs Market Competitve Landscape:

Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, and Pfizer Inc.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/anti-obesity-drugs-market

☛ Segment Covered in the Anti-Obesity Drugs Market:

By Mechanism of Action: Peripherally Acting Drugs, Centrally Acting Drugs.

By Drug Type: Prescription Drugs, OTC Drugs.

By Route of Administration: Oral, Intravenous/Subcutaneous.

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Anti-Obesity Drugs Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=anti-obesity-drugs-market

☛ Regional Analysis for Anti-Obesity Drugs Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Anti-Obesity Drugs Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Anti-Obesity Drugs Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Anti-Obesity Drugs Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.